Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth.

OBJECTIVE We sought to assess whether pharmacological inhibition of hypoxia-inducible transcription factor (HIF)-prolyl hydroxylase enzymes (PHD1, PHD2, and PHD3) is a suitable strategy to stimulate liver regeneration after partial hepatectomy for colorectal liver metastases (CRLM). BACKGROUND Liver regeneration occurs in a hypoxic environment. PHD1 to PHD3 are molecular oxygen sensors and increasingly considered as putative therapeutic targets. However, little is known about the effect of pharmacological PHD inhibition on tumor expansion, and on liver regeneration after surgical resection. METHODS Various mouse models of liver regeneration after extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were applied to assess the effect of the small molecule pan-PHD inhibitor ethyl-3,4-dihydroxybenzoate (EDHB) on liver regeneration and metastatic tumor growth. Metabolism and biodistribution of EDHB were analyzed using liquid chromatography coupled to tandem mass spectrometry. RESULTS EDHB selectively augmented liver regeneration after partial hepatectomy and portal vein ligation, and increased the expression of cell cycle-promoting cyclin proteins, without enhancing metastatic tumor growth. Systemically administered EDHB and its active metabolite 3,4-dihydroxybenzoic acid accumulated in the liver to selectively induce hepatoprotective effects in the liver, but not in tumor tissue, without humoral adverse effects. CONCLUSIONS Pharmacological inhibition of PHDs using EDHB might represent a novel and safe strategy in the treatment of multiple bilobar CRLM.

[1]  A. Ulrich,et al.  Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges , 2015, Hypoxia.

[2]  Xiaohang Zhao,et al.  A Prolyl-Hydroxylase Inhibitor, Ethyl-3,4-Dihydroxybenzoate, Induces Cell Autophagy and Apoptosis in Esophageal Squamous Cell Carcinoma Cells via Up-Regulation of BNIP3 and N-myc Downstream-Regulated Gene-1 , 2014, PloS one.

[3]  Hui-Yi Lin,et al.  YC‐1 inhibits proliferation of breast cancer cells by down‐regulating EZH2 expression via activation of c‐Cbl and ERK , 2014, British journal of pharmacology.

[4]  S. Jegatheeswaran,et al.  Management of colorectal cancer presenting with synchronous liver metastases , 2014, Nature Reviews Clinical Oncology.

[5]  S. Ben-Eliyahu,et al.  The impact of surgical extent and sex on the hepatic metastasis of colon cancer , 2014, Surgery Today.

[6]  W. Huttner,et al.  Loss of Epithelial Hypoxia-Inducible Factor Prolyl Hydroxylase 2 Accelerates Skin Wound Healing in Mice , 2013, Molecular and Cellular Biology.

[7]  G. Semenza,et al.  Collagen prolyl hydroxylases are essential for breast cancer metastasis. , 2013, Cancer research.

[8]  M. Choti,et al.  Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. , 2013, Journal of the American College of Surgeons.

[9]  S. Koenig,et al.  Increased growth of colorectal liver metastasis following partial hepatectomy , 2013, Clinical & Experimental Metastasis.

[10]  M. Mollenhauer,et al.  Deficiency of the oxygen sensor PHD1 augments liver regeneration after partial hepatectomy , 2012, Langenbeck's Archives of Surgery.

[11]  E. Rankin,et al.  The HIF Signaling Pathway in Osteoblasts Directly Modulates Erythropoiesis through the Production of EPO , 2012, Cell.

[12]  C. Eipel,et al.  A critical appraisal of the hemodynamic signal driving liver regeneration , 2012, Langenbeck's Archives of Surgery.

[13]  G. Semenza,et al.  Hypoxia-Inducible Factors in Physiology and Medicine , 2012, Cell.

[14]  R. Schmieder,et al.  Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. , 2010, Journal of the American Society of Nephrology : JASN.

[15]  Robert A. Harris,et al.  Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. , 2010, Gastroenterology.

[16]  Jing Fang,et al.  Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. , 2010, Gastroenterology.

[17]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[18]  M. Beal,et al.  Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity , 2009, The Journal of Biological Chemistry.

[19]  Howard Y. Chang,et al.  Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. , 2009, Cancer cell.

[20]  S. Tashiro.  Mechanism of liver regeneration after liver resection and portal vein embolization (ligation) is different? , 2009, Journal of hepato-biliary-pancreatic surgery.

[21]  Frederik De Smet,et al.  Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization , 2009, Cell.

[22]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[23]  Dong-Hoon Shin,et al.  A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1α , 2008, Molecular Cancer Therapeutics.

[24]  S. Shibahara,et al.  A prolyl-hydroxylase inhibitor, ethyl-3,4-dihydroxybenzoate, induces haem oxygenase-1 expression in human cells through a mechanism independent of hypoxia-inducible factor-1alpha. , 2008, Journal of biochemistry.

[25]  Hasibur Rehman,et al.  Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[26]  Rajiv Jalan,et al.  Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[27]  K. Takeda,et al.  Role and regulation of prolyl hydroxylase domain proteins , 2008, Cell Death and Differentiation.

[28]  E. Rankin,et al.  The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.

[29]  S. Colgan,et al.  Mucosal protection by hypoxia‐inducible factor (HIF) prolyl hydroxylase inhibition , 2008 .

[30]  Robert A. Harris,et al.  Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism , 2008, Nature Genetics.

[31]  G. Wright,et al.  Prolyl hydroxylase inhibitor treatment confers whole‐animal hypoxia tolerance , 2007, Acta physiologica.

[32]  J. Nielsen,et al.  Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity , 2006, Proceedings of the National Academy of Sciences.

[33]  M. Celeste Simon,et al.  Multiple Factors Affecting Cellular Redox Status and Energy Metabolism Modulate Hypoxia-Inducible Factor Prolyl Hydroxylase Activity In Vivo and In Vitro , 2006, Molecular and Cellular Biology.

[34]  Akira Yamanoi,et al.  Expression of hypoxia inducible factor‐1α during liver regeneration induced by partial hepatectomy in rats , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[35]  K. Greulich,et al.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.

[36]  Varda Rotter,et al.  Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. , 2003, Cancer research.

[37]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[38]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[39]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[40]  M. Serra,et al.  Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. , 2000, Journal of hepatology.

[41]  T. Kasten,et al.  Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. , 1988, The Biochemical journal.

[42]  T. Sasaki,et al.  Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a mechanism of action. , 1987, The Journal of biological chemistry.

[43]  K. Majamaa,et al.  Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. , 1986, The Journal of biological chemistry.

[44]  D. Knowles,et al.  Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy. , 1985, Cancer research.

[45]  G. Higgins,et al.  Experimental pathology of the liver , 1931 .